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Available online 25 August 2016Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple sclerosis
(MS); however, treatment beneﬁts may extend beyond walking. MOBILE was a phase 2, 24-week, double-
blind, placebo-controlled exploratory study to assess the impact of 10 mg PR-fampridine twice daily versus pla-
cebo on several subject-assessed measures. This analysis evaluated the physical and psychological health out-
comes of subjects with progressing or relapsing MS from individual items of the Multiple Sclerosis Impact
Scale (MSIS-29). PR-fampridine treatment (n = 68) resulted in greater improvements from baseline in the
MSIS-29 physical (PHYS) and psychological (PSYCH) impact subscales, with differences of 89% and 148% in
mean score reduction from baseline (n = 64) at week 24 versus placebo, respectively. MSIS-29 item analysis
showed that a higher percentage of PR-fampridine subjects had mean improvements in 16/20 PHYS and 6/9
PSYCH items versus placebo after 24 weeks. Post hoc analysis of the 12-item Multiple Sclerosis Walking Scale
(MSWS-12) improver population (≥8-point mean improvement) demonstrated differences in mean reductions
from baseline of 97% and 111% in PR-fampridine MSIS-29 PHYS and PSYCH subscales versus the overall placebo
group over 24weeks. A higher percentage ofMSWS-12 improvers treatedwith PR-fampridine showedmean im-
provements in 20/20 PHYS and 8/9 PSYCH items versus placebo at 24weeks. In conclusion, PR-fampridine result-
ed in physical and psychological beneﬁts versus placebo, sustained over 24 weeks.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Walking impairment1. Introduction
Walking impairment is a common disability among persons with
multiple sclerosis (MS) and has a negative impact on quality of life [1,
2]. Walking disability can reduce independence, with lower limb func-
tion identiﬁed as the most important bodily function in a study of per-
sons with MS [3]. Prolonged-release (PR) oral fampridine, also known
as extended release (dal)fampridine in the US, is currently the only; MS, multiple sclerosis; MSIS-
ultiple Sclerosis Walking Scale;
essive multiple sclerosis; PR,
sclerosis; PSYCH, psychological
sclerosis; SPMS, secondary-
partment of Neurosciences, San
87, 00152 Rome, Italy.
Thousand Oaks, CA 91320, USA.
. This is an open access article underdrug approved to improvewalking in personswithMS [4,5]. In two piv-
otal phase 3 clinical studies, treatment with PR-fampridine resulted in
consistent increases in walking speed versus placebo (25.2% versus
4.7%; P b 0.001), for study subjects assessed as responders (consistently
faster Timed 25-FootWalk [T25FW] times on treatment versus off treat-
ment) [6]. Improvements in the self-assessed 12-itemMultiple Sclerosis
Walking Scale (MSWS-12) were also reported for responders, indepen-
dent of treatment assignment (nominal P b 0.001) [7]. Subsequent
open-label extension studies in responder subjects from the two pivotal
phase 3 studies showed that the efﬁcacy and safety of PR-fampridine
was maintained over a mean exposure of 39.0 and 26.3 months, with
improved walking speed compared with non-responders [8].
Recent studies have demonstrated that the beneﬁts of PR-
fampridine may extend beyond walking speed. Improvements in arm
function, physical and cognitive fatigue, mood and quality of life were
reported in PR-fampridine–treated subjects with MS, who showed im-
provements in walking ability through the T25FW,MSWS-12 or 2-Min-
ute Walk Test [9,10]. The psychological beneﬁts of PR-fampridine werethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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study [11]; however, there have been no data from blinded, placebo-
controlled studies in a similar setting.
The phase 2, 24-week, double-blind, randomised MOBILE study ex-
panded upon the ENABLE study and was the ﬁrst placebo-controlled
study to evaluate the impact of PR-fampridine treatment on mobility,
balance and the subject-perceived health impact of MS, using several
self-assessed measures [12]. Results from the MOBILE study included
greater median improvements from baseline in the 29-item Multiple
Sclerosis Impact Scale (MSIS-29) physical subscale (PHYS) versus place-
bo. Additionally, a higher proportion of subjects treated with PR-
fampridine achieved improvements in the clinically signiﬁcant MSWS-
12 ≥ 8-point reduction threshold [13] versus placebo (P = 0.0153)
[12]. Adverse events were consistent with the established safety proﬁle
of PR-fampridine [12].
This analysis of the MOBILE study evaluated the effect of PR-
fampridine versus placebo on the subject-perceived physical and psy-
chological health impact of MS based on the 29 individual items of the
MSIS-29. The self-administered MSIS-29 questionnaire contains a 20-
item PHYS and a nine-item psychological impact subscale (PSYCH)
and shows good variability, high internal consistency, high test-retest
reliability and good responsiveness to interventions [14,15]. A post
hoc analysis also evaluated MSWS-12 improvers – subjects who were
treated with PR-fampridine and achieved the clinically signiﬁcant ≥8-
point reduction threshold in MSWS-12 score.
2. Materials and methods
2.1. Study design
MOBILE was a 24-week, randomised, double-blind, exploratory,
placebo-controlled phase 2 study (ClinicalTrials.gov identiﬁer
NCT01597297; EudraCT number 2012-000368-90) that enrolled sub-
jects with MS in Europe and Canada. This study explored the effect of
PR-fampridine on self-assessed walking disability and the subjective
impression of well-being in order to further elucidate thresholds for
clinically meaningful changes over 6 months. Study subjects were
randomised to PR-fampridine 10-mg tablets (n = 68) or placebo
(n = 64) twice daily. The study was conducted in compliance with
the Declaration of Helsinki and regulatory requirements, with approval
obtained from local ethics committees and written informed consent
provided by the study subjects. The full methods and results of theMO-
BILE study have been published previously [12].Fig. 1.Design of theMOBILE study. EDSS: Expanded Disability Status Scale; HRQoL: health-relat
12: 12-item Multiple Sclerosis Walking Score.2.2. Subjects
Themain inclusion criteriawere subjects 18 to 70 years of agewith a
diagnosis of progressive or relapsing MS, with a disease duration of
≥3 months and an Expanded Disability Status Scale (EDSS) score of 4.0
to 7.0. Stable concomitant therapies for MS were allowed.
2.3. Study assessments
After a screening period of 14 days, the MSIS-29 PHYS and PSYCH
were assessed at screening visit, day 1 and each on-treatment visit at
weeks 2, 4, 8, 12, 16 and 20, with the last treatment visit at week 24
or upon early termination from the study (Fig. 1). Negative change on
theMSIS-29PHYS and PSYCH subscales indicates improvement in phys-
ical and psychological health, respectively.
2.4. Statistical methods
Mean changes from baseline in the MSIS-29 PHYS and PSYCH sub-
scales were calculated at each study visit, where baseline was deﬁned
as the average score over day 1 and screening. Differences between
the PR-fampridine and placebo groups in the mean reductions for
each visit versus baselinewere given as a percentage. Themean changes
for each of the 20 items of the MSIS-29 PHYS and nine items of the
PSYCH were calculated using all post-baseline visits up to 24 weeks.
For a particular visit, MSIS-29 PHYS and PSYCH scores were calculated
by totalling the individual items and transforming to a scale with a
range of 0 (no impact of MS) to 100 (extreme impact of MS). The per-
centage of study subjects who reported any mean improvement or
worsening in the MSIS-29 PHYS and PSYCH individual items by visit,
or who had a mean improvement of ≥7.0 points over weeks 2 to 24 in
the MSIS-29 PHYS subscale score, were also analysed.
2.4.1. MSWS-12 responder analysis
The MSWS-12 score is a subject-reported, disease-speciﬁc measure
of mobility limitations due toMS over the preceding 2weeks, where re-
ductions in the score indicate improvement [16]. It has been demon-
strated that a ≥ 8-point mean reduction in MSWS-12 score indicates a
clinically meaningful subject-level improvement in walking ability
[13]. Therefore, post hoc subgroup analysis was conducted to stratify
PR-fampridine–treated subjects according to MSWS-12 improver (≥8-
point mean reduction in MSWS-12 score) or MSWS-12 non-improvered quality of life; MS: multiple sclerosis: MSIS-29: Multiple Sclerosis Impact Scale; MSWS-
Table 1
Baseline characteristics.
Characteristic Placebo
(n= 64)
PR-fampridine
(n= 68)
Mean (median) age, years 49.8 (50.0) 49.8 (50.0)
Male, n (%) 31 (48) 30 (44)
White, n (%) 63 (98) 66 (97)
Mean (SD) time since MS diagnosis, yearsa 12.4 (8.4) 10.9 (6.8)
Mean (SD) no. of relapses within past yeara 0.3 (0.7) 0.2 (0.4)
Disease course, n (%)
SPMS 37 (58) 31 (46)
RRMS 20 (31) 24 (35)
PPMS/PRMS 7 (11) 13 (19)
Mean (min–max) EDSS score 5.9 (4.0–7.0) 5.6 (4.0–7.0)
Mean (median) MSIS-29 PHYS subscale score 53.0 (57.5) 50.9 (50.0)
Mean (median) MSIS-29 PSYCH subscale score 36.3 (34.0) 36.0 (32.6)
Mean (median) MSWS-12 score 75.9 (81.3) 71.7 (75.0)
a Placebo, n= 63. EDSS: Expanded Disability Status Scale; max: maximum; min: min-
imum; MS: multiple sclerosis; MSIS-29: Multiple Sclerosis Impact Scale; MSWS-12: 12-
item Multiple Sclerosis Walking Scale; PHYS: physical impact subscale; PPMS: primary-
progressivemultiple sclerosis; PR: prolonged-release; PRMS: progressive-relapsingmulti-
ple sclerosis; PSYCH: psychological impact subscale; RRMS: relapsing-remitting multiple
sclerosis; SPMS: secondary-progressive multiple sclerosis.
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score) status.
For MSIS-29 scores, missing data were imputed using the last obser-
vation carried forward method when at least one post-baseline value
was available. Baseline values were not carried forward. Mean changes
across study subjects were presented at each visit. Treatment differ-
ences were assessed using logistic regression, adjusting for mean base-
line item score. For all analyses of individual items, observed data were
used.
The primary objective of the MOBILE study was to provide an esti-
mate of the effect of PR-fampridine treatment on multiple endpoints,
for which a sample size of 120 study subjects was considered sufﬁcient.
However, this sample size was too small to observe signiﬁcant changes
in the individual item-level analysis of theMSIS-29within the subset of
subjects classiﬁed asMSWS-12 improvers. Therefore, no formal statisti-
cal testing was performed for these analyses.
3. Results
All enrolled subjects were treated and included in this analysis (pla-
cebo, n = 64; PR-fampridine, n = 68). Baseline characteristics were
mostly similar between the groups (Table 1).
3.1. MSIS-29 PHYS and PSYCH subscale scores
PR-fampridine treatment resulted in greater improvements from
baseline in MSIS-29 PHYS subscale scores than those for the placeboM
ea
n 
(m
ed
ian
) c
ha
ng
e
fro
m
 b
as
el
in
e
–10
–8
–6
–4
–2
0
2
MSIS-29 PHYS
40%
reduction
40%
reduction
89%
reduction
D
ire
ct
io
n 
of
 im
pr
ov
em
en
t
PR-fampridine, mean (median)
Week 4  Week 12  Week 24
Fig. 2.Mean (median) change from baseline inMultiple Sclerosis Impact Scale (MSIS-29) physic
PR: prolonged-release.group at weeks 4, 12 and 24 (Fig. 2). The greatest mean improve-
ments from baseline in MSIS-29 PHYS subscale scores were observed
at week 4, while at week 24 there was a difference of 89% between
the PR-fampridine and placebo groups in the change in MSIS-29
PHYS mean subscale score from baseline. Similar results were ob-
served for changes in MSIS-29 PSYCH subscale scores from baseline
at weeks 4, 12 and 24, with a 148% difference between the PR-
fampridine and placebo groups in the mean reduction in score from
baseline at week 24 (Fig. 2).
3.2. Item-level analysis of the MSIS-29 PHYS and PSYCH subscale scores
Study subjects treated with PR-fampridine also showed improved
responses acrossmost of theMSIS-29 PHYS items comparedwith place-
bo; a higher percentage of PR-fampridine subjects reported any mean
reduction in 17 of the 20 individual MSIS-29 PHYS item scores over
12 weeks (Fig. 3a), and in 16 of the 20 individual items over 24 weeks
(Fig. 3b). Post hoc analysis showed that these differences versus placebo
were signiﬁcant in three of the MSIS-29 PHYS items over 12 weeks: dif-
ﬁculties moving around indoors (P= 0.009), having to cut time on work/
other activities (P = 0.020) and taking longer to do things (P = 0.027;
Fig. 3a). Over 24 weeks, there were signiﬁcant differences in the PR-
fampridine group versus placebo in four of the PHYS items: difﬁculties
moving around indoors (P=0.013), difﬁculty doing things spontaneously
(P = 0.012), having to depend on others to do things (P = 0.017) and
taking longer to do things (P = 0.040; Fig. 3b). A higher percentage of
subjects treated with PR-fampridine also showed mean improvements
in six of the nine PSYCH items over 12 and 24 weeks versus placebo
(Fig. 4). This difference was signiﬁcantly greater for PR-fampridine
versus placebo in the post hoc analysis for one item, worries related to
your MS, over 12 weeks (P= 0.044; Fig. 4a) and 24 weeks (P= 0.006,
Fig. 4b).
3.3. Post hoc analysis of the MSIS-29 PHYS and PSYCH subscale scores ac-
cording to MSWS-12 response
Subjects treated with PR-fampridine demonstrated improvements
in MSWS-12 score, with a median change from Baseline to the mean
on-treatment period in MSWS-12 score of−6.9 (95% CI:−11.6,−1.6)
points versus−2.9 (95% CI:−5.4, 1.0) points in placebo-treated sub-
jects (median treatment difference:−3.3 [95% CI:−7.6, 1.2]). Further-
more, a strong correlation was observed between changes in MSWS-12
and MSIS-29 PHYS scores (Pearson's correlation coefﬁcient = 0.768)
and a moderate correlation between MSWS-12 and MSIS-29 PSYCH
scores (Pearson's correlation coefﬁcient = 0.483). Therefore, a post
hoc subgroup analysis was conducted to provide the MSIS-29 subscale
scores and item-level analysis according to MSWS-12 improver (≥8-
point mean reduction in MSWS-12 score) or MSWS-12 non-improver
(b8-point mean reduction, no change, or an increase in MSWS-12M
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Fig. 3. Percentage of study subjectswith anymean improvement in theMultiple Sclerosis Impact Scale physical impact subscale items over (a) 12weeks and (b) 24weeks. *P=0.009; †P=0.020; ‡P=0.027; §P=0.013; ‖P=0.017; ¶P=0.012; **P=
0.040. Items ordered by greatest treatment difference for prolonged-release (PR) fampridine versus placebo at 24 weeks.
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MSWS-12 improvers and 35 as MSWS-12 non-improvers; in the place-
bo group far more subjects were classiﬁed as MSWS-12 non-improvers
(n=46) thanMSWS-12 improvers (n=18). Due the small number of
placebo subjects who showed clinically meaningful improvement on
the MSWS-12, analyses were conducted on the placebo group as a
whole (n= 64).
Subjects classiﬁed as PR-fampridine MSWS-12 improvers (≥8-point
mean improvement) reported an 82% difference in the mean reduction
from baseline in MSIS-29 PHYS subscale scores compared with the pla-
cebo group at week 12 (Fig. 5). A higher percentage of PR-fampridine
MSWS-12 improver subjects also showed any mean improvements in
the MSIS-29 PHYS subscale score over 24 weeks, compared with place-
bo (97% difference in mean reduction).
MSWS-12 improvers also demonstrated a difference of 111% in the
mean reduction in MSIS-29 PSYCH scores from baseline versus placebo
(n=64) at 24weeks. Improvements from baseline observed in the PR-
fampridine MSWS-12 improver population were also greater than the
MSWS-12 non-improvers for both theMSIS-29 PHYS and PSYCH scores
(n= 35).–16
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and 24 in 12-item Multiple Sclerosis Walking Scale (MSWS-12) for improver (≥8-point mean3.4. Improvements in the MSIS-29 PHYS subscale according to MSWS-12
improver status
Thresholds for a clinically meaningful change in the MSIS-29 PHYS
have been proposed to be between 7 and 8 points [17,18]. Therefore,
analyses were also conducted to evaluate the percentages of subjects
who achieved a ≥7-point improvement in the MSIS-29 PHYS subscale
score, by MSIS-12 improver status. In the PR-fampridine MSWS-12 im-
prover group, 82%of subjects had amean improvement of ≥7.0 points in
theMSIS-29 PHYS subscale score, versus 11% of the PR-fampridine non-
improver group or 30% of the placebo group.
3.5. Item-level analysis of the MSIS-29 PHYS and PSYCH scores according to
MSWS-12 improver status
When the MSIS-29 PHYS and PSYCH items were assessed according
to MSWS-12 improver status for PR-fampridine–treated subjects, a
higher percentage of MSWS-12 improvers reported mean reductions
in 19 of the 20 MSIS-29 PHYS items over 12 weeks versus placebo and
non-improvers (Fig. 6a). MSWS-12 improvers also demonstrated aMSIS-29 PSYCH
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Fig. 6. Percentage of 12-itemMultiple SclerosisWalking Scale (MSWS-12) improver, non-improver and placebo subjects with anymean improvement in theMultiple Sclerosis Impact Scale physical impact subscale items fromweek 2 to (a) week 12
and (b) week 24. Items ordered by greatest treatment difference for MSWS-12 improvers versus placebo over 24 weeks.
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mean score reductions across all of the 20 PHYS items over 24 weeks
compared with both the MSWS-12 non-improvers and the placebo
group (Fig. 6b). Differences in the percentage of subjects achieving
any improvement in individual item scores over weeks 2 to 24 were
greatest (N35%) for the following four items when the MSWS-12 im-
prover group was compared with the placebo population: difﬁculties
moving around indoors, taking longer to do things, having to cut time on
work/other activities and having to depend on others to do things.
A higher percentage of MSWS-12 improvers also achieved mean re-
ductions in seven of the nineMSIS-29 PSYCH items compared with pla-
cebo subjects over weeks 2 to 12 (Fig. 7a), and in eight of the nineMSIS-
29 PSYCH items over weeks 2 to 24 (Fig. 7b). There was a higher per-
centage of MSWS-12 improvers with mean reductions in scores across
all MSIS-29 PSYCH items over weeks 2 to 12 and also weeks 2 to 24
compared with MSWS-12 non-improvers. The two items with the
greatest percentage difference (N25%) in study subjects demonstrating
any mean reductions in the MSWS-12 improver group versus placebo
subjects over weeks 2 to 24 were feeling mentally fatigued and worries
related to your MS.
4. Discussion
MS is a debilitating disease that can result in walking impairment
[1,19]. Previous studies have demonstrated an association between
walking speed and quality of life, suggesting that greater walking
disability leads to reduced quality of life [2]. In the pivotal phase 3
clinical studies, PR-fampridine was shown to improve walking abili-
ty [6,7], while post-marketing and placebo-controlled studies also
demonstrated improvements in dynamic and static balance [12,20].
In MOBILE, PR-fampridine showed beneﬁts in subjects with MS on
subject-assessedwalking ability assessed using theMSWS-12, including
numerically larger median improvements compared with placebo [12].
In addition to these beneﬁts, results from the current analyses of the
MOBILE study indicate that PR-fampridine treatment improved the
self-assessed physical and psychological health impact of MS. PR-
fampridine treatment resulted in mean reductions in the MSIS-29
PHYS and PSYCH subscale scores,with a higher percentage of study sub-
jects showing improvements across the majority of the PHYS and
PSYCH items versus placebo. Evaluation of the MSWS-12 improvers
demonstrated that the physical and psychological beneﬁts of PR-
fampridine were improved to a greater extent in those who showed a
clinically meaningful increase in walking speed.
Thresholds for clinically meaningful worsening in theMSIS-29 PHYS
subscale score have been established in both the clinical trial and the
community setting [17,18]. Clinically meaningful worsening in the
MSIS-29 PHYS subscale score was reported as ≥7.5 points in a clinical
trial population [17] and ≥7.0 points in a community setting [18], for
subjects with MS and an EDSS score of 0 to 5 [17]. For subjects based
in a community setting with an EDSS score of 5.5 to 8, the clinically
meaningful threshold for MSIS-29 PHYS subscale worsening was re-
ported as ≥8 points [18]. A threshold for improvement in the MSIS-29
PHYS subscale score has yet to be established, to the authors' knowl-
edge. However, a ≥7-point change in MSIS-29 PHYS subscale score pro-
vides a good estimate of subjects who may be experiencing clinically
meaningful improvements in the MSIS-29 PHYS subscale. The current
analysis showed that the majority of the PR-fampridine–treated
MSWS-12 improver subjects (82%) also showed ≥7-point mean im-
provement in the MSIS-29 PHYS subscale score over weeks 2 to 24 of
treatment. Few subjects (11%, n = 4) in the PR-fampridine MSWS-12
non-improver group met this threshold for improvement in the MSIS-
29 PHYS subscale score. These post hoc results provide additional sup-
port that improvements in walking ability are consistent with better
subject-reported physical functioning.
Progression of the MSIS-29 PHYS and PSYCH subscale scores for the
PR-fampridine population were similar throughout the study,consistent with ﬁndings from the open-label, 48-week ENABLE study
[11]. Improvements observed across both the MSIS-29 PHYS and
PSYCH subscale scores for PR-fampridine–treated subjects in this analy-
sis are consistent with those reported by Hoogervorst et al., who de-
scribed good correlation between PHYS and PSYCH subscale scores
(r= 0.62) in a large, independent population of persons with MS [21].
A Swedish registry study of natalizumab also showed improvements
across both the PHYS and PSYCH subscale scores after 24 months, indi-
cating that physical health improvements are linked to deﬁnable psy-
chological beneﬁts in persons with MS [22]. It should be noted that
the results assessing psychological impact in this analysis showed great-
er variability compared with the physical impact.
Results show that treatment with PR-fampridine improved the sub-
ject-perceived physical health impact of MS, extending ﬁndings from
the open-label ENABLE study, which demonstrated signiﬁcant improve-
ments in themeanMSIS-29 PHYS subscale change from baseline versus
placebo atweeks 12 and 24. Signiﬁcant improvements inMSIS-29 PHYS
subscale score were subsequentlymaintained throughout the 48weeks
of the ENABLE study [11].
Consistent with the improvement in overall MSIS-29 PHYS subscale
score, higher percentages of PR-fampridine–treated subjects demon-
strated reductions in scores across 16 of the 20 individual MSIS-29
PHYS items versus placebo over 24weeks, with differences being statis-
tically signiﬁcant for four items.When study subjects were analysed ac-
cording to whether they achieved a clinically signiﬁcant improvement
on the MSWS-12 (≥8-point mean reduction), greater percentages of
MSWS-12 improvers reported reductions across all of the 20 MSIS-29
PHYS items versus both the placebo and MSWS-12 non-improver pop-
ulations overweeks 2 to 24. As a higher percentage of theMSWS-12 im-
prover group reported improvements across items such as having to
depend on others to do things, taking longer to do things and having to
cut time on work/other activities, the greater independence gained
through improved walking ability in these subjects may lead to a
more active life and improved overall physical outcomes. The results
of the MSIS-29 PHYS item-level analysis of the PR-fampridine–treated
MSWS-12 improver subjects provide further insight into the impact of
improved walking ability on the health-related quality of life of persons
with MS.
The psychological beneﬁts of PR-fampridine treatment reported
here are also consistent with previous reports, with the ENABLE study
demonstrating signiﬁcant improvements (P b 0.001) in the MSIS-29
PSYCH and 36-Item Short Form Health Surveymental component sum-
mary scores at weeks 12 and 24 versus subjects who did not receive
treatment [11]. As reported in previous studies, improvements in walk-
ing ability, arm function, fatigue, mood and quality of life following PR-
fampridine treatment may contribute to the psychological beneﬁts ob-
served here [9,10]. Further evaluation of the beneﬁts observed with
PR-fampridine in the MSIS-29 PSYCH item-level analysis demonstrated
improvements across six of the nine PSYCH items comparedwith place-
bo over 24 weeks. It is worth noting that a higher percentage of PR-
fampridine–treated and MSWS-12 improver subjects reported mean
improvements for theMSIS-29 PSYCH item feelingmentally fatigued ver-
sus placebo, consistentwithﬁndings fromAllart et al., who reported sig-
niﬁcant and prolonged improvements in fatigue after 3 months of
treatment with PR-fampridine [9]. Interestingly, both MSWS-12 im-
prover and non-improver study subjects reported greater mean im-
provements in worries related to your MS compared with placebo.
The MOBILE study showed that PR-fampridine treatment was asso-
ciated with consistent subject-reported improvements in the physical
and psychological measures of MS versus placebo. Analysis of the
MSWS-12 improver population indicated that subjects who experience
clinically meaningful improvements in walking ability show greater
physical and psychological quality of life beneﬁts.
Limitations of this study include a small sample size, the exploratory
nature of the study and that some of the analyses were performed post
hoc. Evaluation of the study subjects following completion of the wash-
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chological beneﬁts versus placebo were attributable to PR-fampridine.
The ﬁndings from this study need to be conﬁrmed in a larger placebo-
controlled study, which is currently underway.
5. Conclusions
The results of the MOBILE study suggest that the beneﬁts of PR-
fampridine extend beyond walking speed and also improve the
subject-perceived physical and psychological impact of MS versus
placebo, particularly in those who show clinically meaningful increases
in walking ability.
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